| 1 |
32647323 | Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. | 2021 Jan |
1 |
| 2 |
33542546 | Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. | 2021 Mar |
1 |
| 3 |
34145036 | CDK6 Is a Therapeutic Target in Myelofibrosis. | 2021 Aug 15 |
1 |
| 4 |
34257712 | Zhike pingchuan granules improve bronchial asthma by regulating the IL-6/JAK2/STAT3 pathway. | 2021 Aug |
1 |
| 5 |
32086626 | Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice. | 2020 Apr |
1 |
| 6 |
31100032 | TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo. | 2019 Aug |
2 |
| 7 |
27957861 | Codelivery of Ponatinib and SAR302503 by Active Bone-Targeted Polymeric Micelles for the Treatment of Therapy-Resistant Chronic Myeloid Leukemia. | 2017 Jan 3 |
2 |
| 8 |
28339658 | Acute cell volume regulation by Janus kinase 2-mediated sodium/hydrogen exchange activation develops at the late one-cell stage in mouse preimplantation embryos. | 2017 Mar 1 |
1 |
| 9 |
26176817 | JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. | 2015 Nov |
1 |
| 10 |
24610827 | Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. | 2014 May 15 |
4 |
| 11 |
18394554 | Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | 2008 Apr |
2 |